非奈利酮降低心肾代谢综合征谱系新发房颤风险:FINE-HEART汇总分析
该预设汇总分析纳入FIDELIO-DKD、FIGARO-DKD和FINEARTS-HF三项试验中基线无房颤/房扑的14581例患者,随机接受非奈利酮或安慰剂。中位随访2.9年,非奈利酮组新发房颤/房扑风险显著低于安慰剂组(HR 0.83,95%CI 0.71-0.97,P=0.019),且风险降低在不同心肾代谢疾病数量和试验间一致。
要点
- 风险降低与心肾代谢疾病数量及试验类型无关(交互P分别为0.87和0.57)。
- 新发房颤/房扑患者后续心血管死亡、心衰住院和肾脏不良结局风险显著更高。
核心结论
- 非甾体类盐皮质激素受体拮抗剂非奈利酮可降低心肾代谢综合征谱系患者新发房颤/房扑的风险。
研究设计与样本
- 预设汇总分析,汇总FIDELIO-DKD、FIGARO-DKD和FINEARTS-HF三项试验,纳入14581例基线无房颤/房扑的患者,1:1随机接受非奈利酮或安慰剂。
- 新发房颤/房扑由盲法临床事件委员会前瞻性判定,采用按地区和试验分层的Cox回归模型评估风险。
主要发现
- 中位随访2.9年,631例(4.3%)发生新发房颤/房扑。
- 非奈利酮组新发房颤/房扑286例(3.9%),安慰剂组345例(4.7%)(HR 0.83;95%CI 0.71-0.97;P=0.019)。
- 风险降低与心肾代谢疾病数量无关(交互P=0.87),与试验无关(交互P=0.57)。
- 新发房颤/房扑的预测因素包括年龄较大、心衰病史、较高体重指数、地理区域和较高尿白蛋白/肌酐比值。
- 新发房颤/房扑患者后续心血管死亡、心衰住院和肾脏不良结局风险显著更高。
临床怎么用
- 在心肾代谢综合征患者中,非奈利酮治疗可能有助于减少新发房颤/房扑,但需结合个体情况评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Mineralocorticoid receptor antagonists (MRA) modulate cardiac and systemic pathways such as fibrosis and inflammation, which may contribute to the onset of atrial fibrillation (AF) or atrial flutter (AFL). OBJECTIVES: In this participant-level pooled analysis of 3 large clinical trials, the authors evaluated the effect of the nonsteroidal MRA finerenone on incident AF/AFL across the cardio-kidney-metabolic (CKM) spectrum. METHODS: In this prespecified analysis, we pooled participants from 2 trials of chronic kidney disease and type 2 diabetes (FIDELIO-DKD and FIGARO-DKD) and a trial of heart failure (HF) with mildly reduced or preserved ejection fraction (FINEARTS-HF). Patients were randomized 1:1 to finerenone or placebo. New-onset AF/AFL was prospectively adjudicated in all trials by blinded clinical event committees. The risk of new-onset AF/AFL was evaluated using Cox regression models stratified by region and trial. RESULTS: Among 14,581 patients who were free of AF/AFL at trial enrollment, 631 (4.3%) experienced new-onset AF/AFL during follow-up. Predictors of new-onset AF/AFL included older age, history of HF, higher body mass index, geographic region, and higher levels of urine albumin-to-creatinine ratio. During 2.9 years of median follow-up, new-onset AF/AFL occurred in 286 (3.9%) participants receiving finerenone and 345 (4.7%) assigned to placebo (HR: 0.83; 95% CI: 0.71-0.97; P = 0.019). Risk reductions were consistent irrespective of number of CKM conditions (Pinteraction = 0.87) and by trial (Pinteraction = 0.57). Participants with new-onset AF/AFL were at significantly higher subsequent risk of cardiovascular death, HF hospitalization, and adverse kidney outcomes. CONCLUSIONS: The nonsteroidal MRA finerenone reduced the risk of new-onset AF/AFL across the CKM spectrum.
引用
- Pabon MA, Filippatos G, Claggett BL, et al. Finerenone Reduces New-Onset Atrial Fibrillation Across the Spectrum of Cardio-Kidney-Metabolic Syndrome: The FINE-HEART Pooled Analysis. J Am Coll Cardiol. 2025. PMID: 40306837. doi:10.1016/j.jacc.2025.03.429
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。